Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 12:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 560 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antiretroviral Therapy (ART) Clear all
Enrolling by invitation Not applicable Interventional

Substance Use and HIV Action for Reentry and Engagement.

NCT06810973
View directory record Official record
Conditions
HIV
Interventions
SUCCESS-E, Enhanced Standard of Care, Key Informant Interviews
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 30, 2026, 12:13 AM EDT
Completed Not applicable Interventional

Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

NCT00000923
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Sep 30, 2026, 12:13 AM EDT
Completed Phase 2 Interventional Results available

Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications

NCT00796822
View directory record Official record
Conditions
HIV, Cardiovascular Diseases, Atherosclerosis
Interventions
Pentoxifylline, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 30, 2026, 12:13 AM EDT
Completed Phase 1 Interventional

Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

NCT00006066
View directory record Official record
Conditions
HIV Infections
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Diphtheria and Tetanus Toxoids Adsorbed, Tetanus and Diphtheria Toxoids Adsorbed, Bacteriophage phi X 174, Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
13
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 30, 2026, 12:13 AM EDT
Terminated Phase 4 Interventional Results available

Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)

NCT01068873
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir plus maraviroc
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 30, 2026, 12:13 AM EDT
Completed No phase listed Observational

Biomarkers to Predict Time to Plasma HIV RNA Rebound

NCT03001128
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Antiretroviral treatment pause
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Sep 30, 2026, 12:13 AM EDT
Completed Not applicable Interventional

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

NCT00001075
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
3
States / cities
Aurora, Colorado • Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 30, 2026, 12:13 AM EDT
Completed Phase 2 Interventional

Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy

NCT00338767
View directory record Official record
Conditions
HIV Infections, Depression
Interventions
Directly Observed Therapy (DOT), Fluoxetine
Behavioral · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Sep 30, 2026, 12:13 AM EDT
Terminated No phase listed Observational

Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents

NCT00207948
View directory record Official record
Conditions
HIV Infections
Interventions
Dose adjustment of Kaletra
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
4 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Sep 30, 2026, 12:13 AM EDT
Completed Not applicable Interventional

A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328

NCT00000943
View directory record Official record
Conditions
HIV Infections
Interventions
Tetanus Toxoid Vaccine, Hepatitis A Vaccine (Inactivated), HIV-1 Immunogen, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
2
States / cities
Iowa City, Iowa • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Sep 30, 2026, 12:13 AM EDT
Recruiting Phase 2Phase 3 Interventional

Impact of Metformin on Immuno-virologic Parameters in HIV

NCT04500678
View directory record Official record
Conditions
HIV/AIDS
Interventions
Metformin
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
40 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 30, 2026, 12:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

NCT01962961
View directory record Official record
Conditions
HIV, Endothelial Dysfunction, Oxidative Stress
Interventions
PharmaNAC (N-acetylcysteine), Matching placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 30, 2026, 12:13 AM EDT
Not listed Phase 3 Interventional

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

NCT00009061
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Nelfinavir mesylate, Lamivudine, GW433908
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
37
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Sep 30, 2026, 12:13 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses

NCT00001108
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Nevirapine, Lamivudine, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 22 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 30, 2026, 12:13 AM EDT
Completed Phase 3 Interventional

Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)

NCT00242840
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
No intervention; Observational study
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
6
States / cities
Fort Lauderdale, Florida • Orlando, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 30, 2026, 12:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Compartmental Biology of HIV in the Male Genital Tract

NCT02638493
View directory record Official record
Conditions
Human Immunodeficiency Virus, Virus Shedding
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 30, 2026, 12:13 AM EDT
Completed Phase 4 Interventional

4-Day-A-Week Treatment Plan for HIV Infected Adolescents

NCT00068809
View directory record Official record
Conditions
HIV Infections
Interventions
Short Cycle Antiretroviral Therapy
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Sep 30, 2026, 12:13 AM EDT
Completed Phase 2 Interventional Results available

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

NCT03639311
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA, RPV LA, RPV, DTG
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Sep 30, 2026, 12:13 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

NCT02120352
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets, RPV Oral Tablets, HAART, RPV
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 30, 2026, 12:13 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating a Clinical Decision Support Tool for Antiretroviral Therapy Optimization

NCT07219862
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Clinical Decision Support System (CDSS), Antiretroviral Therapy, Highly Active, INDIVIDUALIZED THERAPY, AIDS (Acquired Immune Deficiency Syndrome), Personalized Medicine, Precision Medicine
Interventions
smART (Smart Antiretroviral Therapy Assistant), Traditional Prescribing resources
Other
Lead sponsor
Keck School of Medicine of USC
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 30, 2026, 12:13 AM EDT
Withdrawn Phase 1 Interventional

Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer

NCT00003435
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
anti-thymocyte globulin, melphalan, antiviral therapy, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Sep 30, 2026, 12:13 AM EDT
Terminated Phase 1 Interventional Results available

Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study

NCT02531295
View directory record Official record
Conditions
HIV, Human Immunodeficiency Virus
Interventions
Euphorbia kansui extract powder prepared as tea
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Sep 30, 2026, 12:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

NCT00352066
View directory record Official record
Conditions
HIV Infection
Interventions
apricitabine
Drug
Lead sponsor
Avexa
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Sep 30, 2026, 12:13 AM EDT
Terminated Not applicable Interventional

Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention

NCT02818283
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection, Hypercholesterolemia
Interventions
Soy Pretzel, Wheat Pretzel
Dietary Supplement · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Sep 30, 2026, 12:13 AM EDT